

## Title:

### “Latest News in Lymphoma”

#### Abstract:

Lymphomas is a rapidly moving field both as regards translational as well as clinical research. In this presentation I will summarize the latest interesting news, at least from my point of view, which have become known lately and awaiting what will be presented at the next International Conference on Malignant Lymphoma (ICML) in Lugano, June 2015. The connection with ICML is obvious as regards the Lugano Lymphoma Classification, which has just been published in JCO (B. Cheson et al. **Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification**. JCO Sep 20, 2014:3059-3067; DOI:10.1200/JCO.2013.54.8800), which is mainly integrating PET/CT in the staging of malignant lymphomas. As a result of this integration, in many cases the Ann Arbor classification is now becoming obsolete. But PET/CT has an increasing role also as a prognostic tool: this will be discussed in light of the recently published data concerning follicular lymphomas. In diffuse large B-cell lymphomas Rituximab maintenance has proven to be useless, while the role of radiotherapy has been reassessed and reevaluated. The new combination substituting Vincristine for Velcade in the treatment of mantle cell lymphomas has now been shown to be most probably the new standard for the first-line treatment in most patients with mantle cell lymphomas. There is a wealth of new drugs now in phase II-III, which will probably completely change the overall pictures as regards the treatment of many subtypes of malignant lymphomas. The putative role of these new drugs will be discussed.

#### Date:

**1 December  
(Monday)**

#### Time:

**10AM to 11AM**

#### Venue:

**Amphitheatre, Lvl 2  
Duke-NUS Grad Med  
Sch  
8 College Road,  
S169857**  
(Opposite Singapore  
General Hospital, Block  
6/7)

#### Host:

**Bin Tean TEH, Ph.D.**  
Professor  
Program in Cancer &  
Stem Cell Biology  
Duke-NUS Graduate  
medical School  
Singapore  
National Cancer  
Centre Singapore

**“No registration is  
required.”**

Any enquiry, pls contact:  
Nellie Chai

(Tel: 6601 1366)

#### Speaker:



#### **Professor Franco Cavalli, M.D., F.R.C.P (London)**

Scientific Director of the Oncology Institute of Southern Switzerland

#### Biography:

Dr Franco Cavalli, born in 1942, is Scientific Director of the Oncology Institute of Southern Switzerland (IOSI) which has its main location in Bellinzona (Switzerland), but connects all the public hospitals of the Italian speaking part of Switzerland. He created this Institute, which encompasses medical oncology, radio-oncology, nuclear medicine, palliative care, hematology and an important research division. He is Professor (*Titularprofessor*) of medical oncology at the Medical Faculty in Bern (Switzerland). He has an international reputation for the treatment of and research into malignant lymphoma and new drugs. Every second year he organizes in Lugano the International Conference on Malignant Lymphoma, which is the most important congress on this topic worldwide. He has been very active also in the field of the clinical evaluation of new drugs. In this field he was chairman of the Early Clinical Trials Group of EORTC and created the SENDO (Southern Europe New Drug Organization), a conglomerate which included IOSI and the main cancer institutes in Milan. The quality of his work has been recognized by the award of 21 national and international prizes, including the Petzcoller award for special dedication to oncology and the Montaigne prize. He has published more than 500 articles in peer-reviewed journals and has contributed to many books on cancer, including the Textbook of Medical Oncology, which he edited together with S. Kaye (London), H.H. Hansen (Copenhagen) and D. Armitage (Omaha, Nebraska). He was Founding Editor and Editor-in-Chief of Annals of Oncology, Europe's premier medical oncology journal, from 1990 to 2000, and he is on the Editorial Board of several other journals. In 1996, he founded the International Extranodal Lymphoma Study Group (IELSG, [www.ielsg.org](http://www.ielsg.org)), which encompasses now more than 200 institutions in 4 continents. IELSG is the leading cooperative group in the field of the biological and clinical studies in the field of extranodal lymphomas. Franco Cavalli has been President of the Swiss Cancer League and is Chairman of the scientific committee of the European School of Oncology (ESO). He was President of the International Union Against Cancer (UICC) between 2006 and 2008. He was member of the Swiss Parliament between 1995 and 2007.